Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce the development […]

READ MORE read more

Pluriomics in €2M alliance to develop in vitro heart failure models

Leiden, The Netherlands, May 2016: Pluriomics, a Dutch biotech company focusing on the development of fully functional human stem cell-based assay systems, today announced that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development. In this 3 years project, […]

READ MORE read more

News archive

The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk

Date: October 25 – 26, 2016 Location: Arlington, VA, USA  Pluriomics will attend the SOT-hosted meeting: The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk, in Arlington, Virginia. This meeting will engage experts in presenting and discussing various aspects of the phenotype of hiPSC-cardiomyocytes (functional, proteins, biochemical) and comparing them to adult ventricular cardiomyocytes, as a basis for […]

READ MORE read more

WPC: World Preclinical Congress, Europe 2016

Location: Lisbon, Portugal Date: November 15 – 16, 2016 Pluriomics will attend the WPC Europe in Lisbon, Portugal The World Preclinical Congress Europe is a key networking event bringing together a global audience involved in preclinical research. Don’t miss the opportunity to meet Dr. Marijn Vlaming, VP Technology at Pluriomics, who will attend the “Optimizing Leads […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions